United States

Billionaire industrialist Gautam Adani and his nephew Sagar Adani have formally agreed to accept a civil fraud notice from the U.S. Securities and Exchange Commission (SEC), marking a significant procedural development in a case that has captured global attention. With this agreement, they now have 90 days to respond to allegations of misleading U.S. investors related to an alleged bribery scheme tied to solar energy contracts.

Indoco Remedies has received approval from the U.S. Food and Drug Administration for a drug used in the treatment of epilepsy, marking a significant milestone in the company’s international growth strategy. The clearance allows Indoco to market the product in the highly regulated U.S. market, strengthening its presence in the global generics space. Analysts view the approval as a validation of the company’s manufacturing standards and regulatory capabilities.

Shares of several Adani Group companies came under sharp selling pressure after reports emerged that a US regulator had issued summons linked to the conglomerate. The development unsettled market sentiment, triggering a broad-based decline across key listed entities as investors reassessed regulatory and reputational risks. While details of the summons remain limited, the news overshadowed company-specific fundamentals and renewed concerns around governance and overseas scrutiny.

Sun Pharmaceutical Industries has expanded its oncology footprint in the United States with the commercial launch of Unloxcyt, a prescription therapy for the treatment of skin cancer. The introduction underscores the company’s strategy to strengthen its presence in regulated markets by focusing on specialty and complex medicines. The U.S. launch places Sun Pharma in a competitive therapeutic segment marked by high clinical scrutiny and pricing discipline.

Dr. Reddy’s Laboratories has launched a generic version of a widely prescribed eye drop in the United States, marking a strategic expansion of its ophthalmology portfolio. The move underscores the company’s focus on high-growth therapeutic segments and its commitment to providing affordable alternatives in regulated markets. Analysts highlight that entry into the US generic ophthalmic market enhances revenue diversification, leverages regulatory approvals, and positions Dr. Reddy’s to capture market share in a specialized segment.

Air India has cancelled several flights to the United States following the closure of Iranian airspace, a move that has disrupted long-haul international aviation routes between South Asia and North America. The decision underscores how geopolitical tensions in the Middle East continue to ripple across global air travel, forcing airlines to recalibrate operations, reroute aircraft, and prioritize passenger safety. For Air India, the cancellations reflect both operational constraints and rising costs linked to longer flight paths.

Agnivesh Agarwal, son of industrialist Anil Agarwal, has passed away in the United States, according to people familiar with the matter. The news has prompted an outpouring of condolences from business leaders and industry peers, reflecting the Agarwal family’s prominent standing in India’s corporate landscape. While details surrounding the circumstances have not been publicly disclosed, the development marks a moment of personal loss for one of the country’s most well-known business families.

Influenza infections are rising sharply across the United States, placing renewed pressure on healthcare systems and prompting public health agencies to intensify monitoring and prevention efforts. Hospitals in several states report higher-than-usual patient inflows, particularly among children, older adults and individuals with underlying conditions. Health officials attribute the surge to seasonal factors, waning immunity and uneven vaccination coverage. While most cases remain mild to moderate, experts warn that complications could escalate if preventive measures are ignored.

Former U.S. President Donald Trump has once again drawn attention to India’s energy ties with Russia and its tariff regime, framing the issues through the lens of American trade and geopolitical interests. His remarks underscore longstanding tensions in U.S.-India economic relations, particularly around market access, protectionism and strategic alignment. While India has defended its energy purchases as a matter of national interest and affordability, Trump’s comments reflect a broader Western unease over global trade realignments since the Ukraine conflict.

Evolving US control mechanisms over Venezuelan oil exports are reshaping global energy trade and opening a potential Rs. 8,300 crore opportunity for India. As sanctions, licensing regimes and geopolitical negotiations influence the flow of Venezuelan crude, buyers are being forced to adapt. For India, a major crude importer with flexible refining capacity, the situation presents a chance to access alternative supplies at competitive prices while strengthening energy security. However, the opportunity is closely tied to diplomatic alignment and regulatory compliance.